Response definition criteria for ELISPOT assays revisitedZoe Moodie, Cedrik M. Britten, Cécile Gouttefangeas et al.|Cancer Immunology Immunotherapy|2010Cited by 231
Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)Ludwig Heesen, Uğur Şahin, Klaus Kühlcke et al.|Cancer Research|2019Cited by 3
Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)Ludwig Heesen, Uğur Şahin, Katrin Frenzel et al.|Clinical Trials|2019Cited by 2
Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancerKatrin Frenzel, Uğur Şahin, Ludwig Heesen et al.|Annals of Oncology|2017Cited by 2